Janssen Pharmaceutica Nv

Tibotec Pharmaceuticals Ltd.

Janssen R&d Ireland

Sigrid Carl Maria Stokbroekx

Carina Leys

Johan Erwin Edmond Weerts

Yolande Lydia Lang

Lieven Elvire Colette Baert

Andras Horvath

Bart Petrus Anna Maria Jozef Medaer

Tom Cornelis Hortense Govaerts

Joannes Josephus Maria Willems

Stijn Wuyts

Wim Albert Alex Aelterman

Anne Faure

Peter Jozef Maria Van Remoortere

Kelly Ann Swinney

Elisabeth Maria Hélène Egide Ghislaine Theunissen

Yves Georges Ruysschaert

Julius W J Dickens

Ioannes Nicolaos Houpis

Julius Walter Jozef Dickens

Jean François Alexandre Lucas Hegyi

Julius WJ Dickens

This invention provides novel crystalline forms of mono-HCl salts and a mono-HCl salt hydrate of JNJ-26481585, an inhibitor of histone deacetylases. The invention also relates to processes for production of these forms, to intermediates used in these processes, to pharmaceutical compositions comprising these forms, and to the use of these forms in medical treatment for instance as a medicine to inhibit proliferative conditions, such as cancer and leukemia.

Mono-hydrochloric salts of an inhibitor of histone deacetylase

The invention relates to novel polymorphic and hydrate forms and salts of 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline, to methods for their preparation, to pharmaceutical compositions comprising at least one of said polymorphic or hydrate forms or salts, and to the therapeutic and/or prophylactic use of such compositions. The invention also provides new manners for preparing said compound.

Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline

The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.

Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

This invention concerns polymorph I of TMC278, its use and preparation. It further concerns pharmaceutical formulations comprising this polymorph.

Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile

Provided are crystalline forms of the compound of formula (I), which is a macrocyclic inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms. 

Polymorphic forms of a macrocyclic inhibitor of HCV

The object of the present invention is a novel mandelate salt of a substituted tetracyclic tetrahydrofuran derivative according to Formula (I) the N-oxide forms and the stereochemically isomeric forms thereof, wherein Rand Reach independently are hydrogen or Calkyl and Rand Reach independently are hydrogen or halogen. In the foregoing definitions Calkyl defines straight and branched saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylpropyl, 1,1-dimethylethyl, pentyl or hexyl. The novel mandelate salt is not light-sensitive and is far more stable than the prior art salts at room temperature, enhanced temperature and at relative high humidities and in aqueous media. Also disclosed are pharmaceutical compositions comprising mandelate salts according to the invention, mandelate salts according to the invention for use as a medicine, a process for preparing the mandelate salts according to the invention and the use of the mandelate salts and pharmaceutical compositions comprising mandelate salts according to the invention for the treatment or the prevention of CNS disorders, cardiovascular disorders and gastrointestinal disorders.

Mandelates salts of substituted tetracyclic tetrahydrofuran derivatives

Growing community of inventors

Beerse, Belgium

Sigrid Carl Maria Stokbroekx